Granules India Ltd
Granules India Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
The short version
Expectation of significant growth in controlled substances segment over the next 3 to 10 years, with products filed until 2035 (Page 14). Significant growth expected in controlled substances business over next 3 to 10 years with products filed till 2035 (Priyanka Chigurupati). - Ascelis Peptide and Senn Chemicals targeted to turn profitable by Q4 FY'26, with revenue base around $20 million and multiple-fold growth anticipated (Sanjay Kumar). - Base business and peptide business expected to grow at double-digit CAGR from FY'27 onwards, driven by remediation completions and new site approvals (Dr.
From Granules India Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Expectation of significant growth in controlled substances segment over the next 3 to 10 years, with products filed until 2035 (Page 14).
- Products approved 2-3 years ago are gradually gaining market share, contributing to growth in North America (Page 15).
- Formulation business in North America and Europe showed strong year-on-year growth driven by improved operational efficiency and product mix (Page 6).
- Post-remediation and FDA approvals, especially at Gagillapur and GLS facilities, capacity increases will support higher revenues (Pages 12-14).
2 more points from Granules India Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Granules India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company’s net debt increased to Rs. 10,241 million mainly due to increased CAPEX spends in Q2 FY'26.
- CAPEX spend during Q2 FY'26 was Rs. 2,112 million, up from Rs. 1,137 million in Q1 FY'26.
- Additional Rs. 100 crores invested for scaling up CAPEX related to Ascelis Peptide and Senn Chemicals.
- The company continues remediation activities and capacity expansion at various facilities, including transferring some products from Gagillapur to Genome Valley.
2 more points from Granules India Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Granules India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Granules India has a strong foundation for growth, especially in the peptide CDMO segment, backed by rising partnership interests and advancing technology collaborations (Page 6).
- The company has visibility on certain commercial products/projects inherited from prior initiatives, which are currently phased across various quarters and expected to contribute to revenue and profitability in Q4 FY'26 and FY'27 (Pages 11-12).
- Ascelis Peptide and Senn Chemicals combined had a base revenue of just under $20 million, with expectations for multiple-fold growth over the next 1-3 years (Pages 8-9).
2 more points from Granules India Ltd's call on order book
Create a free account to keep reading this call
Granules India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.5K Cr, net profit ₹202 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Granules India's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharmachem Ltd (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Granules India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Granules India Ltd Q2 FY26 results?
Expectation of significant growth in controlled substances segment over the next 3 to 10 years, with products filed until 2035 (Page 14). Significant growth expected in controlled substances business over next 3 to 10 years with products filed till 2035 (Priyanka Chigurupati). - Ascelis Peptide and Senn Chemicals targeted to turn profitable by Q4 FY'26, with revenue base around $20 million and multiple-fold growth anticipated (Sanjay Kumar). - Base business and peptide business expected to grow at double-digit CAGR from FY'27 onwards, driven by remediation completions and new site approvals (Dr.
What is Granules India Ltd share price analysis?
Granules India Ltd currently shows a neutral. The stock trades at a P/E of 34.6 with a market cap of ₹22,514 Cr. Investors should review the full earnings analysis for detailed insights.
Is Granules India Ltd planning capital expenditure?
The company’s net debt increased to Rs.
Keep Granules India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.